This article has been updated to include comments from the company's analyst conference call.

NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its fourth quarter revenues rose 144 percent, due to a 114 percent uptick year over year in the number of Cologuard colon cancer tests it completed during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.